EARLY ADMINISTRATION OF CYTOKINES AFTER RELATED ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES REDUCES DURATION OF APLASIA, HOSPITAL STAY AND TREATMENT-RELATED MORTALITY
S. Martinalgarra et al., EARLY ADMINISTRATION OF CYTOKINES AFTER RELATED ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES REDUCES DURATION OF APLASIA, HOSPITAL STAY AND TREATMENT-RELATED MORTALITY, Blood, 84(10), 1994, pp. 10000093-10000093